Loading...

We've got a brand new version of Simply Wall St! Try it out

IGEA Pharma

SWX:IGPH
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IGPH
SWX
CHF23M
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

IGEA Pharma N.V. provides various medical testing devices and dietary supplements in the United States. The last earnings update was 91 days ago. More info.


Add to Portfolio Compare Print
  • IGEA Pharma has significant price volatility in the past 3 months.
IGPH Share Price and Events
7 Day Returns
5.7%
SWX:IGPH
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
-
SWX:IGPH
33.3%
CH Medical Equipment
12.3%
CH Market
IGPH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IGEA Pharma (IGPH) 5.7% -17.7% -40% - - -
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • No trading data on IGPH.
  • No trading data on IGPH.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

IGPH Value

 Is IGEA Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for IGEA Pharma. This is due to cash flow or dividend data being unavailable. The share price is CHF0.93.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IGEA Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IGEA Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:IGPH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.08
SWX:IGPH Share Price ** SWX (2019-11-14) in CHF CHF0.93
SWX:IGPH Share Price converted to USD reporting currency Exchange rate (CHF/ USD) 1.013 $0.94
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IGEA Pharma.

SWX:IGPH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:IGPH Share Price ÷ EPS (both in USD)

= 0.94 ÷ -0.08

-11.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IGEA Pharma is loss making, we can't compare its value to the CH Medical Equipment industry average.
  • IGEA Pharma is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does IGEA Pharma's expected growth come at a high price?
Raw Data
SWX:IGPH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IGEA Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IGEA Pharma's assets?
Raw Data
SWX:IGPH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.06
SWX:IGPH Share Price * SWX (2019-11-14) in CHF CHF0.93
SWX:IGPH Share Price converted to USD reporting currency Exchange rate (CHF/ USD) 1.013 $0.94
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:IGPH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:IGPH Share Price ÷ Book Value per Share (both in USD)

= 0.94 ÷ 0.06

15.04x

* Primary Listing of IGEA Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IGEA Pharma is overvalued based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess IGEA Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. IGEA Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IGPH Future Performance

 How is IGEA Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IGEA Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.7%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IGEA Pharma expected to grow at an attractive rate?
  • Unable to compare IGEA Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare IGEA Pharma's earnings growth to the Switzerland market average as no estimate data is available.
  • Unable to compare IGEA Pharma's revenue growth to the Switzerland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SWX:IGPH Future Growth Rates Data Sources
Data Point Source Value (per year)
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:IGPH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:IGPH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -2 -2
2019-03-31 0 -2 -2
2018-12-31 0 -1 -1
2017-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if IGEA Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if IGEA Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:IGPH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from IGEA Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:IGPH Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.08
2019-03-31 -0.07
2018-12-31 -0.06
2017-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IGEA Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. IGEA Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. IGEA Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess IGEA Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IGEA Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IGPH Past Performance

  How has IGEA Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IGEA Pharma's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IGEA Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare IGEA Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare IGEA Pharma's 1-year growth to the CH Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
IGEA Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IGEA Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:IGPH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.00 -2.04 1.83
2019-03-31 0.00 -1.69 1.52
2018-12-31 0.01 -1.42 1.28
2017-12-31 0.01 -0.33 0.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if IGEA Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if IGEA Pharma has efficiently used its assets last year compared to the CH Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if IGEA Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess IGEA Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IGEA Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IGPH Health

 How is IGEA Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IGEA Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IGEA Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IGEA Pharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IGEA Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 41.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IGEA Pharma Company Filings, last reported 4 months ago.

SWX:IGPH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.54 0.04 0.99
2019-03-31 2.02 0.00 1.49
2018-12-31 2.55 0.00 2.15
2017-12-31 -1.01 1.47 0.01
  • IGEA Pharma's level of debt (2.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if IGEA Pharma's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • IGEA Pharma has less than a year of cash runway based on current free cash flow.
  • IGEA Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 93.8% each year.
X
Financial health checks
We assess IGEA Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IGEA Pharma has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IGPH Dividends

 What is IGEA Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IGEA Pharma dividends.
If you bought CHF2,000 of IGEA Pharma shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IGEA Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IGEA Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:IGPH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IGEA Pharma has not reported any payouts.
  • Unable to verify if IGEA Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IGEA Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IGEA Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IGEA Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IGEA Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IGEA Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IGPH Management

 What is the CEO of IGEA Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Diego Mortillaro
AGE 50
TENURE AS CEO 1.6 years
CEO Bio

Mr. Diego Mortillaro is a Member of Management Board and Chief Executive Officer at IGEA Pharma N.V. since April 2018. Mr. Mortillaro co-founded Onebip S.r.l in 2005 and served as its Chairman.

CEO Compensation
  • Insufficient data for Diego to compare compensation growth.
  • Insufficient data for Diego to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the IGEA Pharma management team in years:

1.6
Average Tenure
54.5
Average Age
  • The average tenure for the IGEA Pharma management team is less than 2 years, this suggests a new team.
Management Team

Diego Mortillaro

TITLE
CEO & Member of Management Board
AGE
50
TENURE
1.6 yrs

Vinvcenzo Moccia

TITLE
Chairman of the Management Board & CFO
AGE
59
TENURE
1.6 yrs

Rosanna Squitti

TITLE
Chief Medical Officer & Member of Management Board
AGE
50
TENURE
1.6 yrs

Marco Seniga

TITLE
Head of Marketing & Sales and Member of Management Board
AGE
61
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the IGEA Pharma board of directors in years:

0.9
Average Tenure
64.5
Average Age
  • The average tenure for the IGEA Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Giovanni Ferrario

TITLE
Chairman of Supervisory Board
AGE
71
TENURE
0.9 yrs

Flavio Peralda

TITLE
Vice-Chairman of the Supervisory Board
AGE
68
TENURE
0.9 yrs

Mark De Simone

TITLE
Member of Supervisory Board
AGE
61
TENURE
0.9 yrs

Federico Federico Bazzoni

TITLE
Member of Supervisory Board
AGE
59
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess IGEA Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IGEA Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IGPH News

Simply Wall St News

What Kind Of Shareholder Appears On The Igea Pharma N V's (VTX:IGPH) Shareholder Register?

SWX:IGPH Income Statement, July 26th 2019 Hedge funds don't have many shares in Igea Pharma N V. … Insider Ownership Of Igea Pharma N V The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Private Company Ownership We can see that Private Companies own 64%, of the shares on issue.

Simply Wall St -

IGPH Company Info

Description

IGEA Pharma N.V. provides various medical testing devices and dietary supplements in the United States. Its product portfolio includes ALZ Rapid and DBT Rapid that are do-it-yourself finger stick/test to verify if the user has a free copper II level above or below the cut-off value; ALZ1 and DBT1, a lab test to measure the exact free copper II level; 126AGE, a supplement based on a patented molecule to reduce and control free copper II levels in the alzheimer disease prevention process; and 126DBT supplements based on a patented molecule to reduce and control free copper II level in the diabetes type II prevention process. The company also engages in laboratory analysis and management of intellectual property rights. IGEA Pharma N.V. was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.

Details
Name: IGEA Pharma N.V.
IGPH
Exchange: SWX
Founded: 2015
CHF23,295,355
25,048,769
Website: http://www.igeapharma.nl
Address: IGEA Pharma N.V.
Siriusdreef 17,
Hoofddorp,
Noord-Holland, 2132 WT,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX IGPH Registered Shares SIX Swiss Exchange CH CHF 20. Dec 2018
Number of employees
Current staff
Staff numbers
3
IGEA Pharma employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 22:14
End of day share price update: 2019/11/14 00:00
Last earnings filing: 2019/08/15
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.